bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 195,685 shares, a drop of 40.2% from the July 30th total of 327,035 shares. Approximately 2.5% of the shares of the company are short sold. Based on an average daily trading volume, of 361,563 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Investors Weigh In On bioAffinity Technologies

A number of hedge funds have recently added to or reduced their stakes in BIAF. Scientech Research LLC acquired a new stake in bioAffinity Technologies in the third quarter worth about $49,000. Geode Capital Management LLC acquired a new position in bioAffinity Technologies during the 4th quarter valued at about $36,000. Finally, J. Safra Sarasin Holding AG acquired a new position in bioAffinity Technologies during the 1st quarter valued at about $164,000. Institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Price Performance

NASDAQ BIAF opened at $6.59 on Wednesday. The company has a 50 day simple moving average of $9.08 and a 200-day simple moving average of $23.33. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.44 and a quick ratio of 1.41. The firm has a market capitalization of $3.90 million, a price-to-earnings ratio of -0.06 and a beta of -1.04. bioAffinity Technologies has a 52-week low of $4.56 and a 52-week high of $202.50.

bioAffinity Technologies (NASDAQ:BIAF) last posted its earnings results on Friday, August 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($31.50) by $30.86. The company had revenue of $1.51 million during the quarter, compared to the consensus estimate of $1.70 million. bioAffinity Technologies had a negative net margin of 257.30% and a negative return on equity of 220.52%.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Monday, July 20th. Wall Street Zen upgraded bioAffinity Technologies from a “sell” rating to a “hold” rating in a research report on Monday, August 10th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, bioAffinity Technologies currently has an average rating of “Sell”.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.